Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 23Prednisone 16N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Vincristine 11Doxorubicin 11Etoposide 9fludarabine phosphate 8Whole-Body Irradiation 8Mycophenolic Acid 7Lenalidomide 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6Brentuximab Vedotin 6Azacitidine 6Alemtuzumab 6Cyclosporine 5Bortezomib 5romidepsin 4fludarabine 4Tacrolimus 4Rituximab 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4pembrolizumab 3denileukin diftitox 3Transplantation 3Dexamethasone 3Carmustine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Peripheral × Depsipeptides × Clear all
NCT00426764 2020-02-11

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

Celgene

Phase 2 Completed
131 enrolled 16 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00299351 2006-03-06

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.

Royal Marsden NHS Foundation Trust

Phase 2 Unknown
8 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡